If one is on short-term ADT, does the duration of concurrent anti-androgen matter?

Key sentence from the paper: “… for men with no or minimal comorbidity, it appears that the delivery of full versus dose-reduced [anti-androgens] was not associated with prolonged survival…suggesting that supplementing the LHRH agonist therapy with and [anti-androgen] for ~4 rather than 6 months may be sufficient to minimize death from [prostate cancer] and prolong survival as compared with no ADT use.

Read More

ADT reduces men’s quality of life.

Key sentence from the paper: “Overall, QoL [quality of life ] is significantly affected within 12 months of commencing ADT for prostate cancer in men undergoing ADT, above that for a cancer diagnosis alone, prostate cancer progression or radiotherapy.”

Read More

Which is better—continuous or intermittent ADT?

Key sentence from the paper: “[Continuous] ADT is inferior to [intermittent] ADT for the treatment of prostate cancer with respect to cardiovascular-related mortality. No major difference in incidence of cardiovascular events and thromboembolic events were observed between the two groups….

Read More